Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Biogen Inc

Healthcare US BIIB

195.96USD
7.13(3.78%)

Last update at 2026-06-03T20:07:00Z

Day Range

187.48196.50
LowHigh

52 Week Range

115.25202.41
LowHigh

Fundamentals

  • Previous Close 188.83
  • Market Cap27289.75M
  • Volume891384
  • P/E Ratio20.87
  • Dividend Yield-%
  • EBITDA3603.70M
  • Revenue TTM9890.60M
  • Revenue Per Share TTM67.51
  • Gross Profit TTM 7808.20M
  • Diluted EPS TTM8.91

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax 1401.50M 1906.00M 1296.80M 3591.80M 1745.20M
Minority interest 0.00000M 0.00000M -0.40000M 85.30M 171.50M
Net income 1293.39M 1632.20M 1161.10M 3046.90M 1556.10M
Selling general administrative 2433.70M 2319.90M 2430.90M 2403.60M 2623.60M
Selling and marketing expenses - 66.80M 71.40M - -
Gross profit 6913.60M 7365.50M 7302.20M 7895.10M 8872.00M
Reconciled depreciation 779.90M 673.20M 494.80M 365.90M 487.70M
Ebit 2165.20M 2322.50M 1882.20M 2320.20M 2840.70M
Ebitda 3100.60M 2995.70M 2377.00M 2686.10M 3656.60M
Depreciation and amortization 935.40M 673.20M 494.80M 365.90M 815.90M
Non operating income net other - - - 614.50M -1060.60000M
Operating income 1877.50M 2490.30M 2097.30M 2320.20M 2840.70M
Other operating expenses 7933.10M 7185.60M 7738.30M 7271.50M 8173.70M
Interest expense 246.00M 250.30M 246.90M 246.60M 253.60M
Tax provision 263.60M 273.80M 135.30M 632.80M 52.50M
Interest income 125.00M 67.60M 276.50M 89.30M 11.00M
Net interest income -142.50000M -182.70000M 29.60M -157.30000M -242.60000M
Extraordinary items - - - - -
Non recurring - - - 131.10M 18.00M
Other items - - - - -
Income tax expense 108.11M 273.80M 135.30M 632.80M 52.50M
Total revenue 9810.60M 9675.90M 9835.60M 10173.40M 10981.70M
Total operating expenses 5036.10M 4875.20M 5204.90M 4993.20M 6064.00M
Cost of revenue 2897.00M 2310.40M 2533.40M 2278.30M 2109.70M
Total other income expense net -476.00000M -584.30000M -800.50000M 1271.60M -1095.50000M
Discontinued operations - - - - -
Net income from continuing ops 1292.90M 1632.20M 1161.50M 2961.60M 1692.70M
Net income applicable to common shares - - - 3046.90M 1556.10M
Preferred stock and other adjustments - - - - -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 29439.50M 28049.30M 26844.80M 24554.10M 23877.30M
Intangible assets 9178.50M 9691.20M 8363.00M 1850.10M 2221.30M
Earning assets - - - - -
Other current assets 1123.30M 752.50M 1182.00M 1417.60M 1153.10M
Total liab 11182.70M 11333.30M 12045.40M 11165.70M 12917.60M
Total stockholder equity 18256.80M 16716.00M 14799.40M 13388.40M 10959.70M
Deferred long term liab - - - 334.70M 694.50M
Other current liab 2722.20M 2807.70M 838.40M 2781.30M 3299.10M
Common stock 0.10M 0.10M 0.10M 0.10M 0.10M
Capital stock 0.10M 0.10M 0.10M 0.10M 0.10M
Retained earnings 20552.70M 19259.80M 17627.60M 16466.50M 13911.70M
Other liab - - - 1278.90M 2015.00M
Good will 6491.10M 6478.90M 6219.20M 5749.00M 5761.10M
Other assets - - - 1652.90M 3354.60M
Cash 3008.50M 2375.00M 1049.90M 3419.30M 2261.40M
Cash and equivalents - - - - -
Total current liabilities 3349.40M 5528.80M 3434.30M 3272.80M 4298.20M
Current deferred revenue - - 2042.60M - -589.20000M
Net debt 3939.50M 4255.30M 6288.30M 3194.70M 5342.10M
Short term debt 80.40M 1748.60M 150.00M - 999.10M
Short long term debt - 1748.60M 150.00M - 999.10M
Short long term debt total 6948.00M 6630.30M 7338.20M 6614.00M 7603.50M
Other stockholder equity -2114.00000M -2407.70000M -2674.60000M -2913.30000M -2845.40000M
Property plant equipment - - - 3298.60M 3416.40M
Total current assets 8974.10M 7456.80M 6859.30M 9791.20M 7856.50M
Long term investments 431.90M 0.00000M 0.00000M 2234.90M 892.00M
Net tangible assets - - - 5798.80M 2913.80M
Short term investments 807.20M 0.00000M 0.00000M 1473.50M 1541.10M
Net receivables 1867.00M 1868.80M 2100.00M 2136.40M 1549.40M
Long term debt 6286.80M 4547.20M 6788.20M 6281.00M 6274.00M
Inventory 2168.10M 2460.50M 2527.40M 1344.40M 1351.50M
Accounts payable 432.00M 424.20M 403.30M 491.50M 589.20M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - -9.50000M 63.50M
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income -182.00000M -136.20000M -153.70000M -164.90000M -106.70000M
Additional paid in capital - - - - -
Common stock total equity - - - 0.10M 0.10M
Preferred stock total equity - - - - -
Retained earnings total equity - - - 16466.50M 13911.70M
Treasury stock - - - -2977.10000M -2977.10000M
Accumulated amortization - - - - -
Non currrent assets other 431.90M 333.80M 284.30M 1529.20M 1941.00M
Deferred long term asset charges - - - - -
Non current assets total 20465.40M 20592.50M 19985.50M 14762.90M 16020.80M
Capital lease obligations 290.40M 334.50M 400.00M 333.00M 330.40M
Long term debt total - - - 6281.00M 6274.00M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments -1178.60000M -799.20000M -4101.00000M 1576.60M -309.80000M
Change to liabilities - - - -347.70000M -9.10000M
Total cashflows from investing activities -1371.10000M -799.20000M - 1576.60M -563.70000M
Net borrowings -16.90000M -650.00000M - -1002.20000M -170.00000M
Total cash from financing activities -301.90000M -683.50000M 149.30M -1759.70000M -2086.20000M
Change to operating activities - - - -224.40000M -238.70000M
Net income 1292.90M 1632.20M 1161.50M 2961.60M 1727.60M
Change in cash 633.50M 1325.10M -2369.40000M 1157.90M 930.20M
Begin period cash flow 2375.00M 1049.90M 3419.30M 2261.40M 1331.20M
End period cash flow 3008.50M 2375.00M 1049.90M 3419.30M 2261.40M
Total cash from operating activities 2204.60M 2875.50M 1547.20M 1384.30M 3639.90M
Issuance of capital stock - - - - -
Depreciation 779.90M 673.20M 494.80M 518.40M 487.70M
Other cashflows from investing activities -38.70000M 83.90M - 604.10M 4.20M
Dividends paid - - - - 0.70M
Change to inventory -64.70000M -273.80000M -130.90000M -320.20000M -462.40000M
Change to account receivables 42.10M 194.20M 61.30M -203.40000M 324.80M
Sale purchase of stock - 0.00000M 0.00000M -750.00000M -1800.00000M
Other cashflows from financing activities -275.00000M -2.20000M -38.00000M 4.90M -114.80000M
Change to netincome - - - -1471.30000M 743.30M
Capital expenditures 153.80M 359.80M 311.40M 243.20M 294.90M
Change receivables - - - -203.40000M 324.80M
Cash flows other operating - - - 246.90M 828.00M
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - 1213.60M 990.00M
Change in working capital -1057.60000M -155.20000M -648.70000M -890.30000M -145.50000M
Stock based compensation 290.80M 291.20M 264.20M 254.10M 238.60M
Other non cash items 537.00M 592.20M 581.20M -1290.90000M 1758.30M
Free cash flow 2050.80M 2515.70M 1235.80M 1141.10M 3345.00M

Peer Comparison

Sector: Healthcare Industry: Drug Manufacturers - General

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
BIIB
Biogen Inc		 7.13 3.78% 195.96 20.87 12.53 2.76 1.50 3.04 11.54
LLY
Eli Lilly and Company		 14.63 1.37% 1078.78 78.14 31.95 16.34 45.83 16.65 54.36
JNJ
Johnson & Johnson		 0.35 0.16% 223.24 29.17 14.33 3.74 5.18 3.80 15.22
ABBV
AbbVie Inc		 1.73 0.80% 217.13 86.32 14.33 5.89 50.46 7.04 24.44
AZN
AstraZeneca PLC		 -1.17 0.66% 176.28 30.69 19.23 5.30 6.45 5.72 17.23

Reports Covered

Stock Research & News

View All

Profile

Biogen Inc. discovers, develops, manufactures, and delivers therapies in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, and TYSABRI for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; SKYCLARYS to treat Friedreich's Ataxia; QALSODY for treating amyotrophic lateral sclerosis; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE. It offers LEQEMBI for the treatment of Alzheimer's disease; ZURZUVAE for the treatment of postpartum depression; RITUXAN to treat non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for aRelapsed or refractory diffuse large B-cell lymphoma; and other anti-CD20 therapies. Biogen Inc. has collaboration and license agreements with Merz Therapeutics; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; UCB; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis; and Sage Therapeutics, Inc., as well as collaborations with Stoke Therapeutics, Inc. for the development and commercialization of zorevunersen, a disease modifying medicine for the treatment of Dravet syndrome; Dayra Therapeutics, Inc. to develop oral macrocyclic peptides; Vanqua Bio, Inc. for developing Vanqua's preclinical oral C5aR1 antagonist compound; City Therapeutics, Inc. to develop select novel RNAi therapies; and ALTEOGEN Inc. to develop subcutaneous (SC) formulations of biologics utilizing ALT-B4. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.

Biogen Inc

225 Binney Street, Cambridge, MA, United States, 02142

Key Executives

Name Title Year Born
Mr. Michael R. McDonnell CPA Exec. VP & CFO 1964
Ms. Susan H. Alexander Esq. Exec. VP, Chief Legal Officer & Sec. 1957
Mr. Christopher A. Viehbacher Pres, CEO & Director 1960
Ms. Robin C. Kramer Sr. VP & Chief Accounting Officer 1966
Ms. Nicole Murphy Head of Pharmaceutical Operations & Technology NA
Mr. Michael Hencke Head of Investor Relations NA
Ms. Natacha Gassenbach Chief Communication Officer & Head of Corp. Affairs NA
Dr. Ginger Gregory Exec. VP & Chief HR Officer 1968
Dr. Anabella Villalobos Ph.D. Head of Biotherapeutics & Medicinal Sciences 1959
Dr. Sanjay Jariwala Sr. VP of Worldwide Medical NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.